Acorn Research launches AI Healthcare Innovation Lab in Dubai Healthcare City
Dubai - Acorn Research, a Dubai-based pioneer in healthcare advisory and technology, has unveiled its AI Healthcare Innovation Lab during Arab Health 2025. Strategically located in Dubai Healthcare City (DHCC), this state-of-the-art facility is poised to revolutionise healthcare delivery across the UAE, the MENA region and beyond. The lab aims to advance value-based healthcare (VBHC) and improve patient outcomes through AI-driven solutions.
It will also serve as a dynamic collaboration hub, bringing together healthcare professionals, policymakers and AI experts to develop scalable solutions that optimise resource use, standardise medical necessity guidelines and care pathways, and improve patient outcomes.
The launch of the lab aligns with the UAE's vision of fostering cutting-edge healthcare systems and setting global benchmarks, reflecting the strength of DHCC in enhancing healthcare delivery to meet the growing demands of the health sector. Supporting the strategic goals of the Dubai Economic Agenda, D33, the launch uses innovation and digital adoption to preserve and advance Dubai's quality of life.
Ameera Youssef, Chief Executive Officer of Acorn Research, said: 'We are committed to driving a major shift in healthcare — from reactive to proactive care. The AI Healthcare Innovation Lab is a testament to this mission, enabling sustainable, data-driven solutions that place patients at the heart of healthcare transformation. This facility empowers providers, enhances systems for payors and supports authorities in shaping resilient healthcare ecosystems.'
Jaffar Bin Jaffar, Director of Partnerships at Dubai Healthcare City Authority, said: 'The presence of the AI Healthcare Innovation Lab in Dubai Healthcare City underscores its strategic importance as a hub for healthcare excellence and innovation. By fostering collaboration among industry leaders, this initiative elevates Dubai's standing as a pioneer in AI-driven healthcare, setting new benchmarks that resonate globally. The lab represents our shared commitment to advancing patient care and driving sustainable healthcare transformation.'
The key areas of focus include: Value-based Healthcare Platforms , which align care delivery with patient outcomes and payment models; Real-time Clinical Decision Support, empowering physicians with evidence-based care guidelines; AI Genome Analysis, advancing precision medicine for personalised treatments, early disease risk prediction and targeted prevention; Predictive Budgeting and Resource Allocation, offering tools for efficient financial planning, life expectancy and resource distribution; National and Payor Claims Audit Tools, designed to reduce fraud, enhance transparency and streamline reimbursements; Patient-centric VBHC Tools (PROM and PREM), integrating patient feedback into care pathways for continuous improvement; and Population Health Management, leveraging data-driven strategies to improve health outcomes and reduce costs.
Acorn Research began its operations in DHCC and expanded from there, underscoring DHCC's efforts to build a thriving ecosystem for its business partners to grow.
-Ends-
About Acorn Research:
Founded in 2007 in Dubai Healthcare City, Acorn Research has consistently pushed the boundaries of healthcare innovation for almost 2 decades. With a track record of transformational healthcare and digital transformation projects, the company has impacted over 650 healthcare providers and health authorities, driving the adoption of quality improvements in healthcare across the MENA region. Through our commitment to innovation and disruption, Acorn aims to continuously play a pivotal role in positioning Dubai as a leader in the global healthcare industry.
About Dubai Healthcare City:
Established in 2002 by His Highness Sheikh Mohammed Bin Rashid Al Maktoum, Vice President and Prime Minister of the United Arab Emirates and Ruler of Dubai, the Dubai Healthcare City (DHCC) has become the emirate's specialized freezone in health and wellness services, and a leading destination for healthcare investments. The freezone is governed by Dubai Healthcare City Authority (DHCA). DHCC offers a comprehensive range of business solutions covering start-ups to mega healthcare projects, as well as independent and visiting physicians. DHCC, a preferred destination for medical, wellness, academic, and research institutions, complements its offering with a selection of modern lifestyle options, providing its visitors with a wide range of hospitality, shopping, and entertainment features.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
a day ago
- Zawya
Dubai emerges as a regional hub for gene therapy breakthroughs
Medcare Royal Speciality Hospital is pioneering treatments for rare diseases including Spinal Muscular Atrophy and Duchenne Muscular Dystrophy, potentially saving young lives with a single treatment. Dubai – Dubai is rapidly establishing itself as a hub for cutting-edge gene therapy, with Medcare Royal Speciality Hospital Al Qusais being at the forefront of treating rare genetic disorders such as Spinal Muscular Atrophy (SMA) and Duchenne Muscular Dystrophy (DMD). With the hospital's proximity to the Dubai International Airport, a growing number of patients from Turkey, and other countries in the region and beyond are traveling to Dubai for life changing treatments. Medcare has been redefining excellence in the field of paediatric neurology and gene-based therapies, pioneering a new era of hope and healing for families affected by such debilitating conditions. Turkish families are increasingly turning to Medcare for SMA treatments, with incidence rates in Turkey significantly higher than the global average. The hospital's state-of-the-art facilities, international medical expertise, and holistic treatment model position it as a Centre of Excellence for gene disorders, not just in the UAE but across the MENA and the Asia-Pacific regions. SMA, a rare neurodegenerative condition, causes progressive muscle weakness and often proves fatal in infancy if left untreated. In Turkey, SMA affects 1 in every 6,000 births compared to 1 in 10,000 globally [i]. According to the Turkish health authorities, there are currently over 3,000 people living with SMA, and about 150 new cases are diagnosed each year. DMD, another severe neuromuscular disorder, affects over 4,000 genetically confirmed patients in Turkey [ii]. Under the leadership of Dr. Vivek Mundada, a British Board-certified Consultant Paediatric Neurologist at Medcare Royal Speciality Hospital has delivered remarkable outcomes in managing these complex genetic conditions. Unlike traditional therapies that require ongoing spinal injections, Medcare offers a one-time, potentially curative gene therapy that addresses the root cause of the condition, dramatically improving the quality of life and long-term health. Medcare is the first private healthcare provider outside the U.S.A. to successfully administer gene therapy for SMA in the MENA region, having delivered over 100 infusions to date at Medcare Women & Children Hospital. 'Dubai is becoming a center of medical innovation, and Medcare is proud to be leading that movement, especially in the field of rare genetic diseases,' said Dr. Vivek Mundada, Consultant Paediatric Neurologist at Medcare Royal Speciality Hospital. 'Through our comprehensive, patient-centered care model, we are transforming outcomes for children who previously had limited treatment options.' Medcare's approach goes beyond clinical excellence. Patients benefit from a multidisciplinary team that includes experts in neurology, pulmonology, orthopaedics, rehabilitation, and genetic counselling. The hospital also provides continuous follow-up care for international patients after they return home. Turkish families have already seen outstanding results. One such story is that of Mirha, diagnosed with SMA just nine days after she was born. In 2024, she underwent gene therapy at Medcare and is now thriving without the need for breathing or feeding support. Similarly, Elif Bade who was treated in March 2024 when she was just 2 years old, has shown remarkable progress following her gene therapy at Medcare. The parents of Mirha remarked, 'We cannot express enough gratitude to Dr. Mundada and the Medcare team. Thanks to the expert and compassionate care in Dubai, our daughter has been given a new lease on life.' Aligned with the UAE's vision to be a global hub for medical innovation and excellence, Medcare continues to invest in infrastructure, talent, and technology to offer best-in-class care. The newly launched rare disease unit at Medcare Royal Speciality Hospital in Dubai offers AI-powered diagnostics, robotic surgery, and advanced quaternary care, reinforcing its leadership in rare disease management. As part of Aster DM Healthcare, Medcare is committed to expanding access to advanced medical care for international patients, while contributing to the UAE's growing medical tourism sector, where families seek top-tier, cost-effective care without long wait times, especially for critical and time-sensitive conditions like the rare genetic disorders. About Medcare: Medcare is the premium private healthcare provider under the parent group, Aster DM Healthcare. Operating leading state-of-the-art Hospitals, including Medcare Multi-specialty Hospital in Dubai and Sharjah, Medcare Women & Children Hospital, Medcare Orthopaedics and Spine Hospital, and 20 medical centres in the UAE, Medcare has established a strong presence in the UAE. Medcare is dedicated to offering premium integrated health services in accordance with the highest quality. From talent to technology to facilities and treatment, Medcare maintains the highest possible standards in healthcare delivery. All Medcare hospitals and medical centres are accredited by the Joint Commission International (JCI), which is considered the gold standard in global healthcare. Apart from this, Medcare facilities have won several certifications. What sets Medcare apart is its exceptional multi-cultural, multi-lingual team of doctors who have received extensive training from some of the top-notch medical institutes around the world. Using a multidisciplinary approach, the Medcare team provides optimal, evidence-based treatments to patients, with the support of trained nurses, dieticians, rehabilitation therapists and technologists. Living by its simple promise 'We'll Treat You Well', Medcare's team is fully committed to providing high-quality, personalized medical care to every patient. For more information on Medcare visit or follow @Medcareae For media queries, please contact: Akshara Suresh Watermelon Communications Dubai, U.A.E. Email – akshara@
Khaleej Times
a day ago
- Khaleej Times
Future Health GCC Stem Cell Bank launches in-house GMP exosome production facility
Future Health GCC Stem Cell Bank, a recognised leader in stem cell banking and cellular science, has officially launched its new, in-house GMP (Good Manufacturing Practice) exosome production facility at its premises in Dubai Healthcare City. This milestone marks a significant advancement in the company's ongoing efforts to enhance its capabilities in biological processing and life sciences innovation. The newly developed facility enables Future Health GCC to produce GMP-compliant exosome preparations under strict international quality standards. This infrastructure supports a wide range of scientific and research-focused applications, reinforcing the company's position as a technology-forward organisation in the region. Exosomes, which are naturally occurring vesicles secreted by cells, are currently being explored globally for their role in intercellular communication and potential applications in research and biotechnology. Future Health GCC's initiative reflects its commitment to supporting this growing area of scientific study. 'The launch of our GMP exosome production facility is a key milestone that showcases our continuous investment in high-standard, advanced technologies,' said Ahmad Al Ahmad, CEO of Future Health GCC Stem Cell Bank. 'With this addition, we are proud to contribute to the development of the region's biotech infrastructure and facilitate future regenerative medicine' The facility is designed to accommodate scalable exosome production from various cell sources, with processes adhering to international GMP standards. All production batches are handled within tightly controlled environments, and finished products are stored in ultra-low temperature freezers at -80°C, monitored through a cloud-based temperature control system to ensure product consistency and integrity. The new facility will also enable collaboration opportunities with research institutions, biotech startups, and academic entities seeking reliable, quality-controlled exosome products for non-clinical and investigational use.
Khaleej Times
a day ago
- Khaleej Times
NMC Royal Hospital DIP revolutionising breast cancer surgery in the UAE with Sentimag system
The Sentimag system offers a breakthrough alternative by replacing radioactive tracers and blue dye with a safe, non-radioactive technique In a significant advancement for breast cancer treatment in the UAE, NMC Royal Hospital DIP has successfully performed its first breast cancer surgery using the Sentimag system, a cutting-edge, radiation-free technology for sentinel lymph node localisation, marking a major milestone in surgical innovation in the country. The procedure, a first across the entire NMC Healthcare network, was performed at the hospital's dedicated Breast Cancer Clinic by Dr Afaf Sahraoui, specialist in breast, thyroid, and parathyroid surgery, and certified by the Norwegian Health Board. The Sentimag system replaces the conventional use of radioactive tracers and blue dye with a safe, magnetic alternative, enhancing both patient safety and surgical precision. In modern surgical breast cancer surgery, sentinel lymph node biopsy is a crucial step used to determine whether cancer has spread beyond the tumour. Traditionally, this process involves the use of radioactive isotopes and blue dye to locate sentinel lymph nodes which are methods that can pose risks such as radiation exposure, potential allergic reactions and complex logistical challenges due to strict timing of tracer injections. The Sentimag system offers a breakthrough alternative by replacing radioactive tracers and blue dye with a safe, non-radioactive technique. It uses Magtrace, a liquid solution containing magnetic nanoparticles administered before surgery. During the procedure, a handheld probe is used to detect magnetic signals and accurately locate and remove the sentinel lymph node. The same system can also deploy Magseed, a tiny magnetic marker used to localise nonpalpable breast tumours (those not detectable by touch), eliminating the need for traditional guidewires. The first patient to undergo surgery using Sentimag at NMC Royal Hospital DIP was a 47-year-old woman diagnosed with a 26mm invasive breast carcinoma, a malignant tumour that had spread beyond the breast tissue. Following evaluation by a multidisciplinary tumour board, she was recommended for breast-conserving surgery with sentinel lymph node biopsy using the Sentimag system. As the tumour was palpable, Magtrace alone was sufficient, and the procedure was successfully completed through a minimally invasive incision, with the sentinel nodes accurately identified and removed without complications. The technique significantly reduced recovery time, with the patient experiencing minimal discomfort and was discharged just six hours after surgery. She also showed excellent recovery at her one-week postoperative follow-up with no signs of infection. "This technology offers a safer, more convenient, and patient-friendly advancement in breast cancer surgery," said Dr Afaf Sahraoui. "By eliminating the use of radiation and blue dye, we're not only reducing risks but also simplifying the surgical process without compromising diagnostic accuracy. It's a significant step forward for women's health in the UAE." "Sentimag revolutionises sentinel lymph node surgery with a precise, radiation-free alternative,' added Dr Shaista Meraj, consultant radiologist. 'It expands patient access particularly in units like ours, without on-site radioisotopes. This ensures breast clinic efficiency by providing a sustainable and patient friendly alternative to radioactive tracer." The introduction of the Sentimag system reinforces NMC Royal Hospital DIP's commitment to innovation and patient-centred care, making it one of the first hospitals in Dubai to offer this advanced, radiation-free solution for breast cancer surgery. This breakthrough strengthens the hospital's Breast Cancer Clinic offering and reflects NMC Healthcare's ongoing dedication to providing world-class evidence-based treatments to patients across the country.
